Edward Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edward Tran has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Nirmit Shah
University of Melbourne
7 shared publications - Mohamed Aly
Schulich School of Medicine and Dentistry, Western University, Canada
4 shared publications Vivian Phu
Schulich School of Medicine and Dentistry, The University of Western Ontario
4 shared publicationsAngela Kyveris
Ocular Health Centre, Kitchener, ON, Canada
3 shared publicationsNirmit Shah
University of Melbourne
3 shared publications- Ali Hadi
Schulich School of Medicine, University of Western Ontario, London, ON, Canada
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (6) , 1458-1468
Intermediate outcomes of SIBS microshunt in cases of refractory and nonrefractory glaucoma
- 7 September 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (6) , 1458-1468
Open AccessIntermediate outcomes of SIBS microshunt in cases of refractory and nonrefractory glaucoma
- Open Access
- 26 June 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1144-1150
Evaluation of the Deep Reality Viewer for teaching slit-lamp examination of the anterior segment and the optic nerve head
- 26 June 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1144-1150
Open AccessEvaluation of the Deep Reality Viewer for teaching slit-lamp examination of the anterior segment and the optic nerve head
- 30 April 2026
- Published by Taylor & Francis in Strabismus
- Vol. 34 (3) , 1-16
Strabismus surgery outcomes in pediatric patients with developmental delay: a meta-analysis and systematic review
Aligned eyes are crucial for binocular vision, including fusion, stereopsis, and depth perception. Strabismus or misalignment of the eyes can disrupt these abilities potentially leading to complica...
- 30 April 2026
- Published by Taylor & Francis in Strabismus
- Vol. 34 (3) , 1-16
Strabismus surgery outcomes in pediatric patients with developmental delay: a meta-analysis and systematic review
Aligned eyes are crucial for binocular vision, including fusion, stereopsis, and depth perception. Strabismus or misalignment of the eyes can disrupt these abilities potentially leading to complica...
- Open Access
- 6 March 2026
- Published by SAGE Publications in Journal of Visual Impairment & Blindness
- Vol. 120 (2) , 149-164
The Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis
Introduction: Age-related macular degeneration (AMD) is a degenerative retinal disorder leading to central vision loss. This study investigates the association between AMD and sleep quality and sleep duration. Methods: Our team examined a variety of published literature, such as case series, clinical trials, and economic studies. These studies were retrieved from the online databases of peer-reviewed literature, CINHAL, EMBASE, and MEDLINE, as well as literature that was published, but not peer reviewed. We used the statistical analysis software STATA 15.0 to assess for any overall relationships between AMD and sleep quality, sleep duration, or both. Results: Nine articles, with a total of 4,502 subjects, were used to conduct the meta-analysis. There were significantly higher Pittsburgh Sleep Quality Index (PSQI) scores (greater than 5) among AMD patients: effect size (ES) = 0.52, 95%; confidence interval (CI): (0.38, 0.65). These scores indicate that individuals with AMD often have higher PSQI scores, suggesting poorer sleep quality. Furthermore, the meta-analysis showed significantly higher rates of insomnia among AMD patients: ES = 0.02, 95%; CI: (0.01, 0.03). The effect of AMD on sleep time was nonsignificant: ES = 0.04, 95%; CI: (–0.17, 0.25). The odds ratio for sleep time over 8 hr was also not significant among patients with AMD: ES = 0.99, 95%; CI: (0.64, 1.52). Discussion: The findings highlight a significant association between AMD and poor sleep quality, evidenced by higher PSQI scores and increased rates of insomnia among AMD patients. The disruptions in sleep are likely due to the psychological stress associated with vision loss related to AMD, as well as potential disruptions in melatonin synthesis and circadian rhythms. Implications for Practitioners: These results emphasize the need for targeted interventions, such as cognitive-behavioral therapy and melatonin supplementation, to improve sleep quality in this population. Additional studies are needed to elucidate the underlying mechanisms of sleep disturbances in AMD and to assess the efficacy of these treatments.
- 6 March 2026
- Published by SAGE Publications in Journal of Visual Impairment & Blindness
- Vol. 120 (2) , 149-164
Open AccessThe Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis
Introduction: Age-related macular degeneration (AMD) is a degenerative retinal disorder leading to central vision loss. This study investigates the association between AMD and sleep quality and sleep duration. Methods: Our team examined a variety of published literature, such as case series, clinical trials, and economic studies. These studies were retrieved from the online databases of peer-reviewed literature, CINHAL, EMBASE, and MEDLINE, as well as literature that was published, but not peer reviewed. We used the statistical analysis software STATA 15.0 to assess for any overall relationships between AMD and sleep quality, sleep duration, or both. Results: Nine articles, with a total of 4,502 subjects, were used to conduct the meta-analysis. There were significantly higher Pittsburgh Sleep Quality Index (PSQI) scores (greater than 5) among AMD patients: effect size (ES) = 0.52, 95%; confidence interval (CI): (0.38, 0.65). These scores indicate that individuals with AMD often have higher PSQI scores, suggesting poorer sleep quality. Furthermore, the meta-analysis showed significantly higher rates of insomnia among AMD patients: ES = 0.02, 95%; CI: (0.01, 0.03). The effect of AMD on sleep time was nonsignificant: ES = 0.04, 95%; CI: (–0.17, 0.25). The odds ratio for sleep time over 8 hr was also not significant among patients with AMD: ES = 0.99, 95%; CI: (0.64, 1.52). Discussion: The findings highlight a significant association between AMD and poor sleep quality, evidenced by higher PSQI scores and increased rates of insomnia among AMD patients. The disruptions in sleep are likely due to the psychological stress associated with vision loss related to AMD, as well as potential disruptions in melatonin synthesis and circadian rhythms. Implications for Practitioners: These results emphasize the need for targeted interventions, such as cognitive-behavioral therapy and melatonin supplementation, to improve sleep quality in this population. Additional studies are needed to elucidate the underlying mechanisms of sleep disturbances in AMD and to assess the efficacy of these treatments.
- Open Access
- 2 February 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (3) , 591-600
One-year outcomes of an ab externo sibs microshunt in combination with phacoemulsification
- 2 February 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (3) , 591-600
Open AccessOne-year outcomes of an ab externo sibs microshunt in combination with phacoemulsification
- 13 October 2025
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 42 (3) , 253-261
Incidence of Alemtuzumab-Induced Thyroid-Associated Orbitopathy: A Systematic Review and Meta-Analysis
Purpose: Alemtuzumab is a monoclonal antibody that targets CD52 and is commonly used to treat multiple sclerosis. Thyroid dysfunction occurs in 20% to 30% of patients treated with alemtuzumab. This may lead to thyroid-associated orbitopathy (TAO), which can cause debilitating dry eye, diplopia, proptosis, ocular pain, and vision loss. This meta-analysis aims to quantify the incidence of alemtuzumab-induced TAO (AI-TAO) and to characterize its clinical features. Methods: Studies were extracted from Cochrane, Embase (Ovid), Medline (Ovid), and additional gray literature. Using R version 4.4.1 on RStudio, the meta-analysis was conducted using the meta package. Depending on the level of heterogeneity, either a fixed-effects or random-effects model was used to pool the data. Funnel plots were used to assess publication bias. Results: Meta-analysis of 1545 patients across 12 studies revealed that the incidence of alemtuzumab-induced Graves’ disease was 25% (95% confidence interval [CI]: 11–46%) and AI-TAO was 6% (95% CI: 3–10%). Of the patients with established alemtuzumab-induced Graves’ disease, 20% (95% CI: 12–30%) developed TAO. Pooled analysis of 8 studies (n = 556), revealed that the mean onset of AI-TAO was 37.38 months (95% CI: 28.90–46.76). In summary, 51/65 (78.5%) of TAO patients were managed conservatively, and 22/65 (33.9%) were managed surgically. Orbital decompression was required in only 5/65 (7.7%) patients. Conclusions: The incidence of AI-TAO is 6% which is less common than the estimated incidence of 20% to 30% of alemtuzumab-induced thyroid dysfunction. This finding emphasizes the need for patient counseling, baseline ophthalmic examination, and interdisciplinary follow-up for early detection and management of AI-TAO.
- 13 October 2025
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 42 (3) , 253-261
Incidence of Alemtuzumab-Induced Thyroid-Associated Orbitopathy: A Systematic Review and Meta-Analysis
Purpose: Alemtuzumab is a monoclonal antibody that targets CD52 and is commonly used to treat multiple sclerosis. Thyroid dysfunction occurs in 20% to 30% of patients treated with alemtuzumab. This may lead to thyroid-associated orbitopathy (TAO), which can cause debilitating dry eye, diplopia, proptosis, ocular pain, and vision loss. This meta-analysis aims to quantify the incidence of alemtuzumab-induced TAO (AI-TAO) and to characterize its clinical features. Methods: Studies were extracted from Cochrane, Embase (Ovid), Medline (Ovid), and additional gray literature. Using R version 4.4.1 on RStudio, the meta-analysis was conducted using the meta package. Depending on the level of heterogeneity, either a fixed-effects or random-effects model was used to pool the data. Funnel plots were used to assess publication bias. Results: Meta-analysis of 1545 patients across 12 studies revealed that the incidence of alemtuzumab-induced Graves’ disease was 25% (95% confidence interval [CI]: 11–46%) and AI-TAO was 6% (95% CI: 3–10%). Of the patients with established alemtuzumab-induced Graves’ disease, 20% (95% CI: 12–30%) developed TAO. Pooled analysis of 8 studies (n = 556), revealed that the mean onset of AI-TAO was 37.38 months (95% CI: 28.90–46.76). In summary, 51/65 (78.5%) of TAO patients were managed conservatively, and 22/65 (33.9%) were managed surgically. Orbital decompression was required in only 5/65 (7.7%) patients. Conclusions: The incidence of AI-TAO is 6% which is less common than the estimated incidence of 20% to 30% of alemtuzumab-induced thyroid dysfunction. This finding emphasizes the need for patient counseling, baseline ophthalmic examination, and interdisciplinary follow-up for early detection and management of AI-TAO.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 3933-3939
Visual Performance and Refractive Stability of Clareon® Monofocal Intraocular Lens Implanted with an Automated Delivery System
Purpose: To evaluate the visual performance, refractive stability, and glistening-free clarity of the Clareon® monofocal intraocular lens (IOL) implanted using the AutonoMe® automated delivery system in a real-world North American setting. Patients and Methods: A prospective, single-arm study was conducted at a single Canadian site involving 46 patients, or 85 eyes, undergoing cataract surgery with Clareon® IOL implantation. Eligible participants were ≥ 22 years old with best-corrected distance visual acuity (BCDVA) of 0.3 logMAR or worse, targeted for emmetropia, and had < 1.0 D of preoperative astigmatism. Exclusion criteria included retinal disease, glaucoma, amblyopia, corneal pathology, and prior intraocular or corneal surgery. Manifest refraction, uncorrected (UDVA), best-corrected (BCDVA), and low-contrast visual acuity (LCVA) were assessed at 1, 3, and 12 months postoperatively. Glistenings were graded using the Miyata scale at 3 and 12 months. Results: No statistically significant changes were observed in manifest refraction, UDVA, or BCDVA between 1 and 3 months (p > 0.05). At 3 months, the mean spherical equivalent was +0.09 D, with low residual astigmatism (– 0.33 D). Mean logMAR UDVA and BCDVA were 0.13 and 0.02, respectively. LCVA was 0.04 logMAR. No glistenings were observed at either 3 or 12 months in any patient. Refractive and visual outcomes remained stable over time, with no device-related complications reported. Conclusion: The Clareon® IOL demonstrated excellent refractive accuracy, stable visual performance, and sustained optical clarity with no glistenings up to one year postoperatively. Its compatibility with the AutonoMe® delivery system supports its utility as a reliable option for cataract surgery.
- 1 October 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 3933-3939
Open AccessVisual Performance and Refractive Stability of Clareon® Monofocal Intraocular Lens Implanted with an Automated Delivery System
Purpose: To evaluate the visual performance, refractive stability, and glistening-free clarity of the Clareon® monofocal intraocular lens (IOL) implanted using the AutonoMe® automated delivery system in a real-world North American setting. Patients and Methods: A prospective, single-arm study was conducted at a single Canadian site involving 46 patients, or 85 eyes, undergoing cataract surgery with Clareon® IOL implantation. Eligible participants were ≥ 22 years old with best-corrected distance visual acuity (BCDVA) of 0.3 logMAR or worse, targeted for emmetropia, and had < 1.0 D of preoperative astigmatism. Exclusion criteria included retinal disease, glaucoma, amblyopia, corneal pathology, and prior intraocular or corneal surgery. Manifest refraction, uncorrected (UDVA), best-corrected (BCDVA), and low-contrast visual acuity (LCVA) were assessed at 1, 3, and 12 months postoperatively. Glistenings were graded using the Miyata scale at 3 and 12 months. Results: No statistically significant changes were observed in manifest refraction, UDVA, or BCDVA between 1 and 3 months (p > 0.05). At 3 months, the mean spherical equivalent was +0.09 D, with low residual astigmatism (– 0.33 D). Mean logMAR UDVA and BCDVA were 0.13 and 0.02, respectively. LCVA was 0.04 logMAR. No glistenings were observed at either 3 or 12 months in any patient. Refractive and visual outcomes remained stable over time, with no device-related complications reported. Conclusion: The Clareon® IOL demonstrated excellent refractive accuracy, stable visual performance, and sustained optical clarity with no glistenings up to one year postoperatively. Its compatibility with the AutonoMe® delivery system supports its utility as a reliable option for cataract surgery.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 2879-2888
A Retrospective Data Analysis of Patients Treated with Difluprednate and Bromfenac for Cystoid Macular Edema After Uveitis or Cataract Surgery
Purpose: Cystoid macular edema (CME) is a condition which severely limits central vision, often occurring secondary to cataract surgery or uveitis. Although commonly treated with non-steroidal anti-inflammatory agents and a corticosteroid adjunct, an optimal medication regime has not yet been evaluated. Hence, we present a comprehensive analysis of the efficacy and relapse rate associated with various agents to treat CME, such as Bromfenac and Difluprednate. Patients and Methods: A retrospective chart review was conducted on patients aged 18 and above diagnosed with postoperative or uveitic CME via optical coherence tomography from January 1, 2016, to December 31, 2023. Among these eligible patients, we investigated those treated with non-steroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids. The primary outcome was the duration until complete resolution of CME. Secondary outcomes included improvement of CME and the likelihood of CME recurrence after treatment. Statistical analysis involved ANOVA and Tukey’s HSD test to compare treatment efficacy. Results: A total of 518 patients were analyzed. Difluprednate and bromfenac (n = 28) demonstrated the shortest mean resolution time (1.45 months) compared to other combinations. The ANOVA test revealed significant differences among treatment groups (F-value: 6.455, P-value: < 0.00001), and Tukey’s HSD test showed that difluprednate and bromfenac significantly outperformed other medications in treating cystoid macular edema (CME) by reducing resolution times by 5.40 months compared to ketorolac alone (P = 0.0011), 4.76 months compared to ketorolac and prednisolone acetate (P = 0.0001), 5.42 months compared to loteprednol and nepafenac (P < 0.0001), 5.40 months compared to dexamethasone and nepafenac (P < 0.0001), and 4.47 months compared to no treatment (P = 0.0240). Difluprednate and bromfenac also had no cases of CME recurrence. Conclusion: Difluprednate and bromfenac proved to be the most effective treatment regimen for cystoid macular edema (CME), resolving the condition in the shortest amount of time and requiring less frequent dosing.
- 1 August 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 2879-2888
Open AccessA Retrospective Data Analysis of Patients Treated with Difluprednate and Bromfenac for Cystoid Macular Edema After Uveitis or Cataract Surgery
Purpose: Cystoid macular edema (CME) is a condition which severely limits central vision, often occurring secondary to cataract surgery or uveitis. Although commonly treated with non-steroidal anti-inflammatory agents and a corticosteroid adjunct, an optimal medication regime has not yet been evaluated. Hence, we present a comprehensive analysis of the efficacy and relapse rate associated with various agents to treat CME, such as Bromfenac and Difluprednate. Patients and Methods: A retrospective chart review was conducted on patients aged 18 and above diagnosed with postoperative or uveitic CME via optical coherence tomography from January 1, 2016, to December 31, 2023. Among these eligible patients, we investigated those treated with non-steroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids. The primary outcome was the duration until complete resolution of CME. Secondary outcomes included improvement of CME and the likelihood of CME recurrence after treatment. Statistical analysis involved ANOVA and Tukey’s HSD test to compare treatment efficacy. Results: A total of 518 patients were analyzed. Difluprednate and bromfenac (n = 28) demonstrated the shortest mean resolution time (1.45 months) compared to other combinations. The ANOVA test revealed significant differences among treatment groups (F-value: 6.455, P-value: < 0.00001), and Tukey’s HSD test showed that difluprednate and bromfenac significantly outperformed other medications in treating cystoid macular edema (CME) by reducing resolution times by 5.40 months compared to ketorolac alone (P = 0.0011), 4.76 months compared to ketorolac and prednisolone acetate (P = 0.0001), 5.42 months compared to loteprednol and nepafenac (P < 0.0001), 5.40 months compared to dexamethasone and nepafenac (P < 0.0001), and 4.47 months compared to no treatment (P = 0.0240). Difluprednate and bromfenac also had no cases of CME recurrence. Conclusion: Difluprednate and bromfenac proved to be the most effective treatment regimen for cystoid macular edema (CME), resolving the condition in the shortest amount of time and requiring less frequent dosing.
- 1 August 2025
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (2) , 195-202
The Diagnostic Yield of Antiacetylcholine Receptor Antibodies Versus Antimuscle Kinase Antibodies in Ocular Myasthenia Gravis: A Meta-Analysis
Background: Ocular myasthenia gravis (OMG) is an autoimmune disease characterized by autoantibodies targeting postsynaptic proteins at the neuromuscular junction, leading to weakness and fatigability of the levator palpebrae superioris, orbicularis oculi and extraocular muscles. Although OMG is primarily a clinical diagnosis, serological antibody testing, predominantly acetylcholine receptor (AChR) antibodies, is usually performed. The clinical utility of muscle-specific kinase (MuSK) antibodies is less well established in OMG. This meta-analysis evaluates the use of anti-AChR and anti-MuSK in patients with OMG and the relative costs of simultaneous vs sequential testing. Methods: Studies were extracted from Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase (Ovid), Medline (Ovid), and additional gray literature. A systematic review was conducted using Covidence with 2 independent reviewers for study selection and data extraction. The meta-analysis was conducted with R version 4.4.1 on RStudio, and the meta package. Depending on the level of heterogeneity, either a fixed-effects or random-effects model was used to pool the data. Funnel plots were used to assess publication bias. Results: The pooled analysis of 44 studies (n = 4,937 patients with OMG) revealed 59% (95% confidence interval [CI]: 52%–66%) positivity for anti-AChR, whereas the pooled analysis of 34 studies with (n = 3,380) showed 5% (95% CI: 2%–9%) positivity for anti-MuSK. From 62 studies (n = 5,180), 4 patients (0.1%) were doubly seropositive for anti-AChR and anti-MuSK. In patients with OMG positive for AChR antibodies, 5 studies (n = 527) reported a thymoma prevalence of 35% (95% CI: 3%–90%), underscoring the clinical value of anti-AChR testing. Four studies (n= 259) showed that anti-AChR positive patients had a 1.82 (95% CI: 1.15–2.88) times greater risk of progressing from OMG to generalized myasthenia gravis. Conclusions: Almost two-thirds (59%) of the patients with OMG tested positive for AChR antibodies, but MuSK antibodies were only detected in 5% of patients. Positivity for anti-AChR in OMG was associated with a worse prognosis, including a higher prevalence of thymomas and an increased risk of disease generalization. Given the relatively low prevalence of anti-MuSK and the higher cost of anti-MuSK testing, clinicians could consider a stepwise approach to the serological diagnosis of OMG, where anti-MuSK is ordered only if the initial anti-AChR returns negative.
- 1 August 2025
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (2) , 195-202
The Diagnostic Yield of Antiacetylcholine Receptor Antibodies Versus Antimuscle Kinase Antibodies in Ocular Myasthenia Gravis: A Meta-Analysis
Background: Ocular myasthenia gravis (OMG) is an autoimmune disease characterized by autoantibodies targeting postsynaptic proteins at the neuromuscular junction, leading to weakness and fatigability of the levator palpebrae superioris, orbicularis oculi and extraocular muscles. Although OMG is primarily a clinical diagnosis, serological antibody testing, predominantly acetylcholine receptor (AChR) antibodies, is usually performed. The clinical utility of muscle-specific kinase (MuSK) antibodies is less well established in OMG. This meta-analysis evaluates the use of anti-AChR and anti-MuSK in patients with OMG and the relative costs of simultaneous vs sequential testing. Methods: Studies were extracted from Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase (Ovid), Medline (Ovid), and additional gray literature. A systematic review was conducted using Covidence with 2 independent reviewers for study selection and data extraction. The meta-analysis was conducted with R version 4.4.1 on RStudio, and the meta package. Depending on the level of heterogeneity, either a fixed-effects or random-effects model was used to pool the data. Funnel plots were used to assess publication bias. Results: The pooled analysis of 44 studies (n = 4,937 patients with OMG) revealed 59% (95% confidence interval [CI]: 52%–66%) positivity for anti-AChR, whereas the pooled analysis of 34 studies with (n = 3,380) showed 5% (95% CI: 2%–9%) positivity for anti-MuSK. From 62 studies (n = 5,180), 4 patients (0.1%) were doubly seropositive for anti-AChR and anti-MuSK. In patients with OMG positive for AChR antibodies, 5 studies (n = 527) reported a thymoma prevalence of 35% (95% CI: 3%–90%), underscoring the clinical value of anti-AChR testing. Four studies (n= 259) showed that anti-AChR positive patients had a 1.82 (95% CI: 1.15–2.88) times greater risk of progressing from OMG to generalized myasthenia gravis. Conclusions: Almost two-thirds (59%) of the patients with OMG tested positive for AChR antibodies, but MuSK antibodies were only detected in 5% of patients. Positivity for anti-AChR in OMG was associated with a worse prognosis, including a higher prevalence of thymomas and an increased risk of disease generalization. Given the relatively low prevalence of anti-MuSK and the higher cost of anti-MuSK testing, clinicians could consider a stepwise approach to the serological diagnosis of OMG, where anti-MuSK is ordered only if the initial anti-AChR returns negative.
- Open Access
- 7 July 2025
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 29 (3) , 269-278
A comparative study of machine learning models predicting post-hepatectomy liver failure: Enhancing risk estimation in over 25,000 National Surgical Quality Improvement Program patients
Gautham Nair, Ali Hadi, Kartik Gupta, Edward Tran, Geerthan Srikantharajah, Evelyn Waugh, Ephraim Tang, Anton Skaro, Juan Glinka. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.25-046
- 7 July 2025
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 29 (3) , 269-278
Open AccessA comparative study of machine learning models predicting post-hepatectomy liver failure: Enhancing risk estimation in over 25,000 National Surgical Quality Improvement Program patients
Gautham Nair, Ali Hadi, Kartik Gupta, Edward Tran, Geerthan Srikantharajah, Evelyn Waugh, Ephraim Tang, Anton Skaro, Juan Glinka. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.25-046